Immune checkpoint inhibitors plus anlotinib versus anlotinib alone as third-line treatment in advanced non-small-cell lung cancer: a retrospective study

Future Oncology, Ahead of Print.

Source: Future Oncology - July 13, 2021 Category: Cancer & Oncology Authors: Wenjie Zhang Chufeng Zhang Shengjie Yang Qing Chen Chen Wang Qisen Guo Source Type: research